Lalomia Brent 4/A
4/A · CONMED Corp · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
CONMED Executive VP Brent Lalomia Receives 17,198 RSUs
What Happened Brent Lalomia, Executive Vice President, Regulatory Affairs & Quality Assurance at CONMED Corporation (CNMD), was granted 17,198 restricted stock units (RSUs) on 2026-03-02. The RSUs are reported as an award/acquisition at a $0.00 purchase price (standard for equity awards) and are treated as a derivative grant rather than an open-market purchase or sale.
Key Details
- Transaction date: March 2, 2026; Form filed (amendment) on March 18, 2026.
- Grant: 17,198 RSUs; reported acquisition price $0.00 (derivative award).
- Vesting: Per the filing, RSUs are governed by the Company’s 2025 Long-Term Incentive Plan and generally vest over three years (approximately 33% after year 1, 33% after year 2, and 34% after year 3).
- Amendment note: This is a Form 4/A filed to correct the RSU amount—an additional special award of 7,644 RSUs was added to the originally reported 9,554 RSUs for a total of 17,198 (footnote F2).
- Shares owned after transaction: not stated in the provided filing excerpt.
- Transaction type: Award/grant (code A) — compensation, not a market buy or sell.
Context RSUs are a form of equity compensation that give the holder a contingent right to receive company shares if vesting conditions are met; they do not immediately result in tradable shares until vested and released. Grants are routine for executive compensation and should be interpreted as part of pay structure rather than an immediate bullish or bearish trading signal. The filing here is an amendment correcting the grant amount; there is no indication in the filing excerpt of a planned sale, 10b5-1 plan, or tax-withholding disposition.
Insider Transaction Report
- Award
RSUs (Restricted Stock Units)
[F1][F2]2026-03-02+17,198→ 17,198 totalExercise: $0.00Exp: 2036-03-02→ Common Stock (17,198 underlying)
Footnotes (2)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.
- [F2]This Form 4/A is filed solely to correct the amount of RSUs granted. A special award of 7,644 shares was awarded in addition to the originally reported 9,554 shares for a total of 17,198 RSUs granted.